Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05866432 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases

Study acronym: TUXEDO-2
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 25, 2025 (before its estimated May 23, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Site details revisedv4
  2. Start date changed from estimate of May 23, 2023 to Jul 1, 2023v3
  3. Trial status: Not Yet Recruiting to Recruiting Site details revisedv2 Show 1 more changeShow less
    • Site details revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Datopotamab-deruxtecan in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases.
Trial Details
NCT Number NCT05866432
Lead Sponsor Medical University of Vienna
Collaborators: Daiichi Sankyo
Conditions Breast Cancer Stage IV
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov